Download PDF
Klin Monbl Augenheilkd 2017; 234(10): 1259-1265
DOI: 10.1055/s-0042-123834
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Retinaler Venenverschluss – wann, womit und wie therapieren?

Retinal Vein Occlusion – Which Treatment When?
A. Bajor
Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover
,
A. Pielen
Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover
,
L. Danzmann
Universitätsklinik für Augenheilkunde, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

eingereicht 19 October 2016

akzeptiert 27 October 2016

Publication Date:
04 April 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nach neuesten Erkenntnissen ist ein Makulaödem infolge eines retinalen Venenverschlusses am besten mit einer zeitnahen intravitrealen Anti-VEGF-Therapie (Aflibercept, Bevacizumab [off label], Ranibizumab) sicher und effektiv behandelbar. Nach einem anfänglichen Upload von monatlich 3 Injektionen Anti-VEGF sollte in regelmäßigen Kontrollen vor allem OCT-basiert (bevorzugt gegenüber visusbasiert) über eine erneute Injektion entschieden werden. Nach anfänglichen monatlichen Injektionen haben sich derzeit vor allem das „Pro-re-nata“- (PRN) und das „Treat-and-Extend“-Schema in Bezug auf den weiteren Therapieverlauf durchgesetzt. Unter Beachtung des Nebenwirkungsspektrums (insbesondere Kataraktprogression, Augeninnendruckerhöhung) kann auch eine intravitreale Therapie mit einem Dexamethason-Implantat sinnvoll sein. Die Prognose bez. Visus und Rückgang des Makulaödems hängt von einem frühen Behandlungsbeginn mit konsequenter Therapiefortführung ab. Vor Behandlungsbeginn sowie im Verlauf ist eine Fluoresceinangiografie nötig, um ischämische Netzhautareale zu detektieren. Es gibt Hinweise, dass eine frühe gezielte Laserkoagulation ischämischer Netzhautareale die Frequenz der nötigen Injektionen senkt und zu einem besseren Ansprechen des Ödems auf die Therapie führt. Bei signifikanter retinaler Ischämie, die in der Folge zu Proliferationen, Rubeosis iridis und einem Sekundärglaukom führen kann, ist eine Laserbehandlung unumgänglich.

Abstract

According to the latest findings, macular oedema due to retinal vein occlusion is best treated safely and effectively with near-term intravitreal anti-VEGF therapy (aflibercept, bevacizumab [off label], ranibizumab). After an initial upload of 3 monthly injections of anti-VEGF, the decision on re-injection should be based on OCT (rather than on visual acuity). After initial monthly injections, the “pro-re-nata” (PRN) and the “treat-and-extend” regimens have been predominantly used in the further course of therapy. Taking into account the side effect spectrum (in particular cataract progression, increased intraocular pressure), intravitreal therapy with a dexamethasone implant may be a reasonable alternative. The prognosis for visual acuity and the decline in macular oedema depend on starting treatment early and continuing it consistently. Before starting treatment, as well as during treatment, fluorescein angiography is necessary to detect ischemic retinal areas. There is evidence that early targeted laser coagulation of ischemic retina may reduce the frequency of necessary injections and improve the response of the oedema to therapy. Significant retinal ischemia may lead to proliferations, rubeosis iridis and secondary glaucoma and therefore requires laser treatment.

Schlüsselwörter

retinaler Venenverschluss - Zentralvenenverschluss - Venenastverschluss - Makulaödem - Anti-VEGF

Key words

retinal vein occlusion - CRVO - BRVO - macular edema - anti-VEGF
 

  • Literatur

  • 1 Feltgen N, Pielen A. [Retinal vein occlusion: Epidemiology, classification and clinical findings]. Ophthalmologe 2015; 112: 607-618
    CrossrefPubMedGoogle Scholar
  • 2 Feltgen N, Pielen A. [Retinal vein occlusion: Therapy of retinal vein occlusion]. Ophthalmologe 2015; 112: 695-704
    CrossrefPubMedGoogle Scholar
  • 3 Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118: 119-133.e2
    CrossrefPubMedGoogle Scholar
  • 4 Feltgen N, Pielen A. Hansen Let al. [Intravitreal drug therapy for retinal vein occlusion – pathophysiological mechanisms and routinely used drugs]. Klin Monatsbl Augenheilkd 2010; 227: 681-693
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lang G, Lang S. Diagnostik und Therapie retinaler Venenverschlüsse. Klin Monatsbl Augenheilkd 2010; 227: R141-R155
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Bertelsen M, Linneberg A, Christoffersen N. et al. Mortality in patients with central retinal vein occlusion. Ophthalmology 2014; 121: 637-642
    CrossrefPubMedGoogle Scholar
  • 7 Werther W, Chu L, Holekamp N. et al. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol 2011; 129: 326-331
    CrossrefPubMedGoogle Scholar
  • 8 Pielen A, Feltgen N, Isserstedt C. et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PloS One 2013; 8: e78538
    CrossrefPubMedGoogle Scholar
  • 9 Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. . 2010; 227: 542-556
    PubMed
  • 10 Coscas G, Loewenstein A, Augustin A. et al. Management of retinal vein occlusion – consensus document. Ophthalmologica 2011; 226: 4-28
    CrossrefPubMedGoogle Scholar
  • 11 Berger AR, Cruess AF, Altomare F. et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 2015; 234: 6-25
    CrossrefPubMedGoogle Scholar
  • 12 Haller JA, Bandello F, Belfort R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
    CrossrefPubMedGoogle Scholar
  • 13 Mayer W, Hadjigoli A, Wolf A. et al. Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab als Erstbehandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen. Klin Monatsbl Augenheilkd 2015; 232: 1289-1296
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Huang P, Niu W, Ni Z. et al. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PloS One 2013; 8: e82454
    CrossrefPubMedGoogle Scholar
  • 15 Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013; (01) CD009510
    PubMedGoogle Scholar
  • 16 Braithwaite T, Nanji AA, Lindsley K. et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2014; (05) CD007325
    PubMedGoogle Scholar
  • 17 Hattenbach L-O. Efficacy and safety of 0.5 mg Ranibizumab compared with 0.7 mg dexamethasone intravitreal implant in patients with branch retinal vein occlusion over 6 months: The COMRADE-B study. Invest Ophthalmol Vis Sci 2014; 55: 1830
    PubMedGoogle Scholar
  • 18 Hoerauf H, Feltgen N, Weiss C. et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European label study. Am J Ophthalmol 2016; 169: 258-267
    CrossrefPubMedGoogle Scholar
  • 19 Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011; 25: 661-672
    CrossrefPubMedGoogle Scholar
  • 20 Xu L, Lu T, Tuomi L. et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 2013; 54: 1616-1624
    CrossrefPubMedGoogle Scholar
  • 21 Ferrara N, Damico L, Shams N. et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870
    CrossrefPubMedGoogle Scholar
  • 22 Holash J, Davis S, Papadopoulos N. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99: 11393-11398
    CrossrefPubMedGoogle Scholar
  • 23 Brown DM, Heier JS, Clark WL. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155: 429-437.e7
    CrossrefPubMedGoogle Scholar
  • 24 Papadopoulos N, Martin J, Ruan Q. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185
    CrossrefPubMedGoogle Scholar
  • 25 Avery RL, Castellarin AA, Steinle NC. et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98: 1636-1641
    CrossrefPubMedGoogle Scholar
  • 26 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049
    CrossrefPubMedGoogle Scholar
  • 27 Campochiaro PA, Sophie R, Pearlman J. et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. Ophthalmology 2014; 121: 209-219
    CrossrefPubMedGoogle Scholar
  • 28 Wecker T, Ehlken C, Bühler A. et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 2016; DOI: 10.1136/bjophthalmol-2016-308668.
    CrossrefPubMedGoogle Scholar
  • 29 Chin-Yee D, Eck T, Fowler S. et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 2015; DOI: 10.1136/bjophthalmol-2015-306987.
    CrossrefPubMedGoogle Scholar
  • 30 Rayess N, Houston SKS, Gupta OP. et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015; 159: 3-8.e1
    CrossrefPubMedGoogle Scholar
  • 31 Campochiaro PA, Wykoff CC, Singer M. et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 2014; 121: 2432-2442
    CrossrefPubMedGoogle Scholar
  • 32 Clark WL, Boyer DS, Heier JS. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123: 330-336
    CrossrefPubMedGoogle Scholar
  • 33 Larsen M, Waldstein SM, Boscia F. et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL Study. Ophthalmology 2016; 123: 1101-1111
    CrossrefPubMedGoogle Scholar
  • 34 Pielen A, Mirshahi A, Feltgen N. et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 2015; 93: e29-e37
    CrossrefPubMedGoogle Scholar
  • 35 Wang K, Wang Y, Gao L. et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31: 1541-1546
    CrossrefPubMedGoogle Scholar
  • 36 McAllister IL, Vijayasekaran S, Chen SD. et al. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009; 147: 838-846
    CrossrefPubMedGoogle Scholar
  • 37 Kunikata H, Shimura M, Nakazawa T. et al. Chemokines in aqueous humour before and after intravitreal triamcinolone acetonide in eyes with macular oedema associated with branch retinal vein occlusion. Acta Ophthalmol 2012; 90: 162-167
    CrossrefPubMedGoogle Scholar
  • 38 Ip MS, Scott IU, VanVeldhuisen PC. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114
    CrossrefPubMedGoogle Scholar
  • 39 Scott IU, Ip MS, VanVeldhuisen PC. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128
    CrossrefPubMedGoogle Scholar
  • 40 Haller JA, Bandello F, Belfort R. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.e3
    CrossrefPubMedGoogle Scholar
  • 41 Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012; 119: 132-137
    CrossrefPubMedGoogle Scholar
  • 42 Jeanneteau F, Garabedian MJ, Chao MV. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci U S A 2008; 105: 4862-4867
    CrossrefPubMedGoogle Scholar
  • 43 Augustin AJ, Holz FG, Haritoglou C. et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 2015; 233: 18-26
    CrossrefPubMedGoogle Scholar
  • 44 Schmitz K, Maier M, Clemens CR. et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe 2014; 111: 44-52
    CrossrefPubMedGoogle Scholar
  • 45 [Anonymous] Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986; 104: 34-41
    CrossrefPubMedGoogle Scholar
  • 46 [Anonymous] A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 1434-1444
    CrossrefPubMedGoogle Scholar
  • 47 Tomomatsu Y, Tomomatsu T, Takamura Y. et al. Comparative study of combined bevacizumab/targeted photocoagulation vs. bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol 2016; 94: e225-e230
    CrossrefPubMedGoogle Scholar
  • 48 Rehak M, Tilgner E, Franke A. et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 2014; 252: 745-752
    CrossrefPubMedGoogle Scholar
  • 49 Campochiaro PA, Hafiz G, Mir TA. et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology 2015; 122: 1426-1437
    CrossrefPubMedGoogle Scholar